Alteration of haemostasis in non-metastatic gastric cancer

Background. Cancer is one of the most common acquired causes of venous thromboembolism. Aim. To evaluate haemostasis disorders in patients with non-metastatic gastric cancer. Patients and methods. We studied 11 patients with non-metastatic gastric cancer (9 males and 2 females, median age 54 years)...

Full description

Saved in:
Bibliographic Details
Published in:Digestive and liver disease 2001-10, Vol.33 (7), p.546-550
Main Authors: Di Micco, P., Romano, M., Niglio, A., Nozzolillo, P., Federico, A., Petronella, P., Nunziata, L., Di Micco, B., Torella, R.
Format: Article
Language:English
Subjects:
Activated Protein C Resistance
Case-Control Studies
Female
Fibrin Fibrinogen Degradation Products - analysis
Fibrinogen - analysis
Fibrinolysis
haemostasis
Hemostasis - physiology
Humans
Male
Middle Aged
non-metastatic gastric cancer
Partial Thromboplastin Time
prothrombin fragment 1+2 (F 1+2)
Prothrombin Time
Stomach Neoplasms - blood
Stomach Neoplasms - complications
Thrombin - analysis
Thromboembolism - blood
Thromboembolism - etiology
Tissue Plasminogen Activator - analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. Cancer is one of the most common acquired causes of venous thromboembolism. Aim. To evaluate haemostasis disorders in patients with non-metastatic gastric cancer. Patients and methods. We studied 11 patients with non-metastatic gastric cancer (9 males and 2 females, median age 54 years) and 20 healthy subjects (15 males and 5 females, median age 48 years) control. We measured prothrombin time, activated partial thromboplastin time, coagulation time, clot lysis time, fibrinogen, clotting factors (II, VII, VIII, IX, X), C protein, S protein, AT Ill, activated protein C resistance, prothrombin 1+2 fragment, tissue plasminogen activator, and D-Dimer in all subjects. Results. Fibrinogen plasma levels were significantly higher in patients with non-metastatic gastric cancer than in control group (505±24 mg/dl vs 336±30 mg/dl, p
ISSN:1590-8658
1878-3562
DOI:10.1016/S1590-8658(01)80105-5